快速变化的IgA脏病治疗环境
Chee Kay Cheung1, Jonathan Barratt1
1Department of Cardiovascular Sciences, University of Leicester, Leicester, UK; John Walls Renal Unit, University Hospitals of Leicester NHS Trust, Leicester, UK.
Seminars in nephrology
|March 8, 2025
概括
最近的进展改变了IgA病 (IgAN) 治疗,有三种新疗法获得批准,更多正在开发中. 本综述探讨了新的Igan药物开发,并提出了未来的治疗方法.
科学领域:
- 科和免疫学 科和免疫学
- 药理学和药物开发领域
背景情况:
- 最近,IgA病 (IgAN) 治疗领域发生了重大变化.
- 越来越多地了解IgAN病原和监管变化刺激了药物开发.
研究的目的:
- 审查IgA脏病的新疗法背后的逻辑.
- 总结Igan治疗的新出现的临床试验数据.
- 为IGAN.提议一种新的治疗模式.
主要方法:
- 关于IgA病的最新科学文献的综述.
- 对已批准和正在研究的IgAN疗法进行临床试验数据的分析.
- 综合信息,提出未来的治疗策略.
主要成果:
- 三种新疗法 (nefecon,sparsentan,iptacopan) 已被批准用于Igan治疗.
- 其他多种Igan疗法正在临床开发的后期阶段.
- 新出现的数据支持这些新治疗方案的有效性.
结论:
- 对IgA病的治疗正在经历显著的转变.
- 新的治疗方案为IGAN患者提供了改进的管理策略.
- 需要修改治疗模式,以纳入这些进展.
相关概念视频
Inflammatory Bowel Disease IV: Pharmacological Management
86
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
86
Open Angle Glaucoma: Treatment
383
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
383
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
130
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
130
Antihypertensive Drugs: Direct Renin Inhibitors
468
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
468
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
107
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
107
Transcytosis of IgG
2.7K
Transcytosis is the process in which molecules are internalized by endocytosis, transported across the cell, and released through exocytosis from the opposite end of the cell. Molecules such as insulin, immunoglobulins, and certain nutrients are transferred through the recycling endosomes by recycling and transcytosis.
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
IgG molecules from a mother undergo transcytosis starting around 13 weeks of gestation. The amount of IgG transferred and entering the fetal blood circulation increases with...
2.7K


